Teva Oncology—the oncology division of Teva Pharmaceuticals—is one of the top 10 oncology companies in the US.*1
Today we provide multiple therapies for hematologic malignancies and an approved
supportive cancer care treatment.
Our diverse pipeline of small molecules
and biologics holds great promise for future therapies in hematologic malignancies,
solid tumors, and supportive care.
By combining our global heritage with therapeutic innovation, we provide more treatment
choices for patients with cancer.
Committed to the
of cancer care
Drawing upon Teva’s more than 100 years of healthcare expertise,
Teva Oncology comes from a long and proud heritage of making
quality healthcare accessible around the world.
Located in more than 60 countries, Teva is recognized as one of
the top 10 pharmaceutical companies worldwide. Over 1.5 million
Teva prescriptions are written daily in the US—in
fact, 1 of every
6 prescriptions dispensed is a Teva product.
With a global presence of 34 research and development
centers, more than 60 manufacturing sites, and more
than a decade of investment in the development and
manufacture of biologics, Teva takes pride in its
culture of innovation and quality.
We work hard to ease the way for people
with cancer throughout their therapeutic
journey. Helping with reimbursement and
offering patients educational materials are
just some of the ways we make high-quality
healthcare accessible to people with cancer.
We recognize that to make a real difference
in cancer care, we have a responsibility to help
support the members of the oncology community
that we serve—patients, healthcare professionals,
and patient advocates. We are proud to invest in
patient care through educational programs and
sponsorships of cancer support organizations.
Helping to fund lifesaving research and support
for people battling cancer as a national sponsor
of the Leukemia & Lymphoma Society’s Light The
Recognizing excellence in the HCP community
by sponsoring programs such as the T.O.P.
Pharmacist award, which honors outstanding
Enhancing opportunities for patient advocates
by supporting the Conquer Cancer Foundation,
which awards educational scholarships annually
to attend the ASCO Annual Meeting.